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0959-8049/ª 2020 Elsevier Ltd. All righAbstract Since its outbreak in the last December, coronavirus disease 2019 (COVID-19)
caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus
is regarded as a global public health emergency. The existing therapeutic options for
COVID-19 beyond the intensive supportive care are limited, with an undefined or modest ef-
ficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use
approved drugs outside the scope of their original indication and accelerate the discovery of
new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely
applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs
for the treatment of COVID-19, which are under investigation in clinical trials or proposed for
the clinical testing.
ª 2020 Elsevier Ltd. All rights reserved.a (K. El Bairi).
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Novel coronavirus disease 2019 (COVID-19) has
recently emerged as a potential life-threatening disease
of public health interest, worldwide. Few pharmaco-
therapeutic options are available at the present time,
and patients are experiencing adverse outcomes in the
most severe presentations. The treatments used in the
clinical care are mainly based on supportive measures
and intensive care management for complicated cases
[138]. Antiviral, antibiotic and antimalarial molecules
have also been used to avoid severe outcomes as well as
plasma therapy from recovered patients [12,19,75].
Despite the lack of strong evidence from clinical trials,
several pharmacological treatments have been used in
clinical practice and included in possible protocols based
on preliminary findings of promising efficacy and a
rationale against COVID-19, as suggested by recent
systematic reviews [37,217]. However, if available, clin-
ical trials remain the option of choice for patients with
COVID-19, to enhance the data and progress in medical
research. In this context, drug repurposing can be an
attractive and promising approach for patients with
COVID-19 in order to benefit from the safety and
effectiveness of the molecules with proposed antiviral
and/or immunomodulating properties [80,142]. Repur-
posed pipelines may have a significant impact, particu-
larly in this critical time [44,78,161]. In this review
article, we discuss the potential of a number of com-
pounds licensed for cancer conditions that seem to have
a rationale to target some pathogenic key mechanisms
of COVID-19, under clinical investigation or proposed
for clinical trials.2. Drug repurposing as a substitute solution for emerging
viral diseases of public health interest
The development of novel antiviral drugs requires long-
term investigations in clinical trials. The advantage to
repurpose drugs to validate off-label use is related to the
known safety profile, though it may vary across the
diseases, and consolidated data of pharmacodynamics,
pharmacokinetics and efficacy in phase IeIV trials. Of
interest, some host cellular targets interfering with the
viral growth cycle, such as kinases, are broadly shared in
the mechanisms of several viral infections and other
conditions such as cancer, suggesting the possibility to
translate knowledge across medical disciplines and dis-
ease models [56,156]. Therefore, pharmacologic ap-
proaches for targeting key pathogenic mechanisms, such
as signalling pathways, constitute a promising tactic
during outbreaks of emerging pathogens. A cost-
effective drug repurposing has been previously used to
combat intracellular pathogens as an urgent alternative
during the occurrence of rapidly spreading and deadly
infectious diseases: in fact, repurposed medicines mayhelp reduce the investments in the earlier phases of drug
development, with an immediate use in the specific
setting of unmet need [66,118]. For instance, an accu-
mulated experience on repurposed therapeutics during
previous outbreaks caused by Ebola virus, dengue virus,
severe acute respiratory syndrome coronavirus (SARS-
CoV), Zika virus and Middle Eastern respiratory syn-
drome coronavirus (MERS-CoV) has led to the estab-
lishment of a rationale for synergistic drug combinations
[9,20,32,47,213]. For example, the use of sofosbuvir plus
ribavirin treatment, which is a combination of a nucle-
otide polymerase inhibitor and a synthetic antiviral
nucleoside analogue approved for hepatitis C infection
by the Food and Drug Administration (FDA) [187], has
been repurposed for treating Zika virus infection. The
two antiviral drugs were all tested in vivo for Zika dis-
ease and showed promising efficacy [22,57,160], thus
prompting the clinical testing [16]. The antiprotozoal
nitazoxanide developed by Romark Laboratories is
another important example [1,6]. Nitazoxanide is a
thiazolide that triggers the host immune response by
potentiating interferon release, interfering with post-
translational stage of viral haemagglutinin and intra-
cellular trafficking [157,191]. This drug showed potential
properties with its broad-spectrum effects on other mi-
crobes encompassing Mycobacterium leprae [10], human
norovirus [40] and Ebola virus [95]. Additionally, it has
also been repurposed for influenza and is being tested in
late-phase clinical trials ([79] (for details, see:
NCT03336619, NCT02612922, NCT01227421 and
NCT01610245). Meanwhile, nitazoxanide is presently
under investigation in two randomised clinical trials
(NCT04343248 and NCT04341493) for COVID-19.
Romark is a phase III, randomised, double-blind,
placebo-controlled trial evaluating the efficacy and
safety of nitazoxanide (twice daily for 6 weeks) for post-
exposure prophylaxis of COVID-19 in 300 patients
(NCT04343248). A phase IV trial is already currently
enroling patients with COVID-19 and will compare
nitazoxanide-hydroxychloroquine to hydroxy-
chloroquine alone (NCT04341493). Hydroxy-
chloroquine is an antimalarial drug that has been shown
to interfere with the late-stage entry process of viruses
based on cellular endocytic pathways. It is currently
being investigated worldwide in more than 70 urgent
clinical trials for COVID-19 (https://www.clinicaltrials.
gov; accessed 14-04-2020). However, emerging
evidence from a randomised and controlled phase III
trial comparing hydroxychloroquine alone or with
azithromycin versus standard care treatments for
hospitalised patients with mild to moderate disease did
not show clinically significant improvements after 15
d of treatment [25]. In the real world, similar results
were obtained in an observational study with a larger
cohort [68]. Notably, the latest meta-analysis with
Bayesian examination of 29 studies including three
randomised trials on this topic found evidence against
Fig. 1. A: SARS-CoV-2 structure. B: A simplified illustration of the targetable pathways by anticancer drugs in COVID-19. For details,
see text. Abbreviations: ACE2: angiotensin-converting enzyme 2, IL-6: interleukin 6, RNA: ribonucleic acid, TMPRSS2: transmembrane
protease serine 2.
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with azithromycin in this setting [58].3. Druggable targets in COVID-19-host signalling
pathways
COVID-19 exhibits mild to moderate symptoms, which
may progress into severe pneumonia, with lymphopenia,
and an exhausted cytokine release syndrome [24]. The
disease is caused by a novel strain of coronaviruses
(SARS-CoV-2) that emerged in NovembereDecember
2019, probably naturally selected in an animal host
before zoonotic transfer. However, SARS-CoV-2 has
then crossed the animal species barriers and acquired the
capacity of human-to-human infection, resulting in a
rapid spread of COVID-19 at a pandemic proportion [83].
The SARS-CoV-2 is closely related to the previous
strain SARS-CoV-1 that has caused the SARS epidemic
in China during the period 2002e2004 [216]. SARS-
CoV-2 is an enveloped, non-segmented and single-
stranded RNA virus and belongs to the sarbecovirus
subgenus of the Coronaviridae family [226]. The ultra-
structure of SARS-CoV-2 is characterised by four key
proteins, namely surface spike S glycoprotein, envelope
protein E, membrane protein (M) and nucleocapsid
protein (N) (Fig. 1A).
The mechanisms of infectivity and pathogenesis of
this coronavirus are poorly known and seem to besimilar to those of SARS-CoV and MERS-CoV [106]
(Fig. 1B). The host cell entry of SARS-CoV-2 depends
on angiotensin-converting enzyme 2 (ACE2) and
transmembrane protease serine 2 (TMPRSS2)
[86,205,207]. Human cells with rich cell-surface receptor
ACE2, an important modulator involved in the blood
pressure regulation, are susceptible to SARS-CoV-2
infection. According to the recently emerged evidence,
the elucidated crystal structure of SARS-CoV-2 showed
that its receptor-binding domain (RBD) has an
enhanced affinity to bind to the human ACE2 [167]. The
receptor-binding motif of the RBD mediates the contact
with ACE2. Two virus-binding hotspots at the
RBDeACE interface are stabilised by several residue
changes of amino-acids in SARS-CoV-2 as compared to
the previous SARS-CoV-1 [167]. The entry into cells
requires the protein S of the viral spike that binds to the
receptor ACE2 facilitated by some host cell proteases,
such as TMPRSS2 [71,173]. This phenomenon, based on
protein S priming, enables fusion of viral and cellular
membranes and escapes from antiviral humoral immune
response [71,173]. This interaction seems to be target-
able by inhibiting host proteases [86,169].
The marketed orally bioavailable camostat mesylate
approved in Japan for the treatment of chronic
pancreatitis and reflux oesophagitis after gastrectomy
[101,123] demonstrated a significant inhibition of
TMPRSS2 [86], suggesting a potential role to treat
COVID-19. These effects were also observed in prostate
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associated with suppression of metastasis in vivo [109].
In addition, the use of soluble human ACE2 can inhibit
early stage SARS-CoV-2 infections as revealed by a
recent study including human organoids, by using the
recombinant ACE2 as a decoy receptor [121]. Fig. 1B
shows an overview about the potential targets for
COVID-19 therapy.
After the fusion of viral and host cell membranes, the
virus accesses by the endosomal pathway, facilitated by
cathepsins (cysteine pH-dependent proteases) [18,144].
The virus dissembles and releases its nucleocapsid and
RNA material into the host cell cytoplasm via caveolae-
and clathrin-mediated endocytosis [215]. This pathway
involves phosphatidylinositol binding clathrin assembly
protein (PICALM), which is a cargo-selecting clathrin
adaptor that drives membrane curvature during endocy-
tosis [90,119]. The PICALM is a target of chloroquine that
suppresses its expression [90,209], inhibiting in this way the
clathrin-mediated endocytosis process. The genomicRNA
of SARS-CoV-2 contains open reading frames, which are
translated into two replicase polyproteins (pp1a and pp1b)
[55]. Therefore, the replicase transcriptase complex (RTC)
is generated by processing pp1a and pp1b to produce non-
structural proteins (16 putative NSPs), which form RNA
polymerase and helicase that have a central role in the
transcription and replication of coronaviruses [26,195].
The RTC attaches to the endoplasmic reticulum (ER)
membranes and produces double-membrane vesicles of
the coronavirus. A part of the RTC undergoes other mo-
lecular changes for mRNA synthesis and splicing to
generate the structural and accessory proteins of the virus.
The glycoproteins of the envelope will reach the ER and
Golgi apparatus in which they form with the nucleocapsid
protein and the viral RNA the vesicle containing the virion
[26]. After assembly via the EReGolgi intermediate
compartment, the release of the new virion-containing
vesicles from the infected host cells is achieved by exocy-
tosis [26,31]. An alternative cell surface non-endosomal
route for coronavirus entry involves TMPRSS2 that
cleaves the spike glycoprotein into S1 and S2 subunits [26].
This enables a fusion of the membranes of the coronavirus
and target cell. Of note, TMPRSS2 is druggable by
camostat that demonstrated efficacy as a single treatment
in lung cell entry blockade of MERS-CoV [172].
The SARS-CoV-2 action on host immunity encom-
passes innate and adaptive immune response activation.
Unfortunately, local and systemic uncontrolled inflam-
matory response as well as altered adaptive immune
reactions can damage organ tissues [24]. Leukopenia
and lymphopenia with reduced natural killer (NK) cells
in addition to increased C-reactive protein can be seen in
patients with severe COVID-19 [24,27]. A marked
decrease of total CD8þ T cells and NK translates the
early failure of antiviral immunity during SARS-CoV-2
infection [223]. Upregulation of the expression of CD94/
NK group 2 member A (NKG2A) by these immune cellssuggested a functional exhaustion of cytotoxic lym-
phocytes in the development of COVID-19 [223]. These
features can result in high mortality and more severity of
the disease [27,91,92,146].
Elevated serum levels of pro-inflammatory cytokines
(known as cytokine release syndrome or cytokine storm),
such as tumour-necrosis factor alpha (TNF-a) and inter-
leukin 6 (IL-6), seem to cause multiple organ failure by
damaging tissues, contributing to the poor outcomes in
COVID-19 patients [14,24,70,117,159,210,218,220].
Notably, immunosuppression obtained with drugs tar-
geting IL-6 axis such as tocilizumab (Actemra, Gen-
entech) or siltuximab (Sylvant, Janssen) has been
proposed [61,117,134,221]. Based on these assumptions,
several phase III trials are currently ongoing
(NCT04320615, NCT04345445 and NCT04330638).
However, at least for tocilizumab, the clinical use in hos-
pitalised patients with severe COVID-19 has not met the
expectations in randomised clinical trials (COVACTA/
NCT04320615), and areas of implementation are now
explored to identify possible predictive biomarkers of
benefit for a subset of selected patients [124]. Finally, the
pro-inflammatory microenvironment in COVID-19-
associated lung failure induces massive infiltration of im-
mune cells and damages the alveolar tissues. This mecha-
nism increases vascular permeability and alveolar fluids
accumulation, which is a hallmark of the deadly acute
respiratory distress syndrome (ARDS) [115]. Both the
mechanisms of immune-escape in COVID-19 might be
potentially targetable and should be urgently delineated.4. Potential anticancer drugs for COVID-19
4.1. Ruxolitinib
Ruxolitinib is a potent orally bioavailable Janus kinase
(JAK) 1 and JAK2 inhibitor indicated for various
myeloproliferative malignancies including myelofibrosis
and polycythemia vera [3,198,200]. These neoplasms,
alongside with the acute myeloid leukaemia, are known
by their aberrant activation of the JAK-STAT signalling
[199]. This pathway plays a pivotal role in cell prolifer-
ation and survival and seems to be targetable for a
spectrum of conditions beyond malignancies.
Regarding COVID-19, ruxolitinib was recently repur-
posed to quell the immune-hyperactivation, thus damp-
ening the cytokine storm and improving ARDS. An
artificial intelligence-driven study has identified ruxolitinib
as a promising drug for COVID-19 along with other
molecules capable to disrupt the JAK-STAT signalling,
used for myelofibrosis and rheumatoid arthritis, such as
baricitinib and fedratinib [181]. The clinical trials using
ruxolitinib for COVID-19 are summarised in Table 1. In
particular, ruxolitinib is being investigated against placebo
for COVID-19 patients with ARDS in two randomised
phase III trials (NCT04362137 and NCT04377620). The
Table 1
Summary of potential anticancer drugs for repurposing in COVID-19.
Anticancer drug Mechanism of action Viralehost targets Tested in clinical
trials for COVID-19?
(country)









NCT04348071 Hospitalised patients Cumulative incidence of
Grade 3 and 4 AE; eight-
point ordinal scale
October 2021
NCT04359290 Severe lung disease Overall survival July 2021
NCT04355793 Hospitalised patients Description of the disease
course
Not provided
NCT04354714 Critical disease Overall survival Withdrawn
NCT04362137 Hospitalised patients Proportion of patients who
die, develop respiratory














Recovery of pneumonia June 2020
NCT04374149 Critical disease Overall response rate April 2021
NCT04338958 Severe lung disease Overall response rate August 2021
NCT04337359 Critical disease Description of the disease
course
Not provided
NCT04331665 Disease requiring O2-
support
Rate of clinical worsening February 2021
NCT04361903 Disease requiring O2-
support




NCT04348695 Hospitalised patients Rate of clinical worsening May 2020
NCT04424056  Eligible patients for
resuscitation care in
UCI





VEGF Yes (France and
China)
NCT04275414 Severe lung disease or
critical disease
Change of PaO2 to
FiO2 ratio
May 2020
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No e e e e
Zotatifin Inhibition of protein
biogenesis
Blockade of eIF4A No e e e e
Plitidepsin Interference with the
viral cycle
Blockade of eEF1A Yes (Spain) NCT04382066 Hospitalised patients Frequency of occurrence of
Grade 3 or higher AEs
November 2020




No e e e e




No e e e e
Leronlimab Immune homeostasis
restoration
Disruption of the CCL5/
RANTES-CCR5
pathway
Yes (USA) NCT04343651 Mild/moderate disease Clinical improvement September 2020
NCT04347239 Severe lung disease or
critical disease





Yes (China) ChiCTR2000029806 Severe lung disease Proportion of patients with














NCT04333914 Disease requiring O2-
support
28-day survival rate Suspended
NCT04356508 Clinically stable patients
with mild or moderate
disease and
asymptomatic patients





Yes (Spain) NCT04335305 Severe lung disease or
critical disease
Percentage of patients with
normalisation of
SpO2 96% on room air
September 2020







NCT04357613 Hospitalised patients Rate of prevented severe
disease worsening
December 2021
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III,multicentred, randomised (2:1) and placebo-controlled
trial, which evaluates the safety and efficacy of ruxolitinib
added to best supportive care in patients with cytokine
storm. The RUXCOVID-DEVENT (NCT04377620) is a
phase III, placebo-controlled trial, which is currently
evaluating ruxolitinib for the treatment of COVID-19
patients with ARDS requiring mechanical ventilation.
Both the phase III trials are designed for clinically critical
patients, aiming to tackle the pathological immune
response and control the hyper-inflammatory syndrome in
more severe patients. In addition, another ongoing phase
III trial (NCT04424056) combines multiple immune sup-
pressors including anakinra (an anti-IL-1 inhibitor), toci-
lizumab, in association with ruxolitinib for more severe
COVID-19 cases, including ARDS, associated with
possible cytokine storm and other immune dysregulations.
4.2. Carmofur
Carmofur (1-hexylcarbamoyl-5-fluorouracil) is an old
pyrimidine analogue and a lipophilic masked compound
of fluorouracil. Its mechanism of action is independent
of 5-fluorouracil-antitumour activity, based on the in-
hibition of the lysosomal acid ceramidase [43,148]. The
upregulation of acid ceramidase is linked to survival and
growth of cancer cells as well as drug resistance [23].
This enzyme is an emerging target for several malig-
nancies [74], such as prostate cancer [108] and glioblas-
toma [130] as well as paediatric brain tumours [45]. In
addition, carmofur exerts its antiproliferative and anti-
metastatic effects through the blockade of the Wnt/b-
catenin signalling pathway [107]. This molecule has been
previously tested in clinical trials for the treatment of
colon cancer as single or in combination with other
chemotherapeutics [162] and in early breast cancer [122].
Recently, carmofur has been found to block SARS-
CoV-2 replication by inhibiting the viral protease
through the covalent binding between the carbonyl
reactive group and the catalytic Cys145. In another
molecular modelling report, Gao et al. indicated that
carmofur strongly bound to SARS-CoV-2 Mpro [63].
This suggests that repurposing low-molecular weight
drugs such as carmofur against the main protease of
SARS-CoV-2 based on in silico studies may show a
therapeutic potential. Importantly, the identification of
the specific mechanisms of viral blockade provided the
paradigm to design analogues of carmofur, with
improved efficacy for COVID-19 and less neurotoxicity.
This last aspect is particularly relevant because of its
association with drug-related leukoencephalopathy.
4.3. Bevacizumab
Bevacizumab is a monoclonal antibody with anti-
angiogenic properties, capable to target the vascular
endothelial growth factor [64]. This biological agent has
K. El Bairi et al. / European Journal of Cancer 141 (2020) 40e61 47been successfully implemented in the clinic management
of various cancer types, including advanced ovarian
cancer, renal cell carcinoma as well as colorectal cancer
in combination with chemotherapy [49,64]. The key
mechanism of bevacizumab is related to the disruption
of the malignant neo-angiogenesis, ultimately reducing
the abnormal vascular permeability and nutrients supply
to cancer cells. Based on this mechanism [15,208], the
use of bevacizumab has been proposed for the control of
the abnormal angiogenesis and the related vascular
permeability undermining the accumulation of intra-
alveolar fibrin deposition, resulting in ARDS and
occurring during COVID-19 disease. A recent study
found that new vessel growth induced by intussusceptive
angiogenesis in the lungs of COVID-19 patients is
approximately three times higher than in the lungs of
patients with influenza [2]. Therefore, bevacizumab is
being investigated also in this field (NCT04344782,
NCT04305106 and NCT04275414). More in detail, the
BEST-CP clinical trial (NCT04275414) (n Z 20) is a
Chinese pilot study that is currently recruiting patients
with COVID-19 to be treated with intravenous bev-
acizumab (500 mg flat dose) with the aim to control the
pulmonary oedema. Another multicentred and rando-
mised trial in China is investigating the safety and effi-
cacy of bevacizumab (7.5 mg/kg) in COVID-19 patients
with severe pneumonia (NCT04305106). Additionally,
the French CORIMMUNO-BEVA phase II trial
(NCT04344782) is randomising COVID-19 patients to
receive bevacizumab (7.5 mg/kg) versus best of the
standard supportive care (Table 1). Based on the pro-
posed mechanism of action, the use of bevacizumab is
now included in clinical trials for more severe patients,
presenting with the clinical features of ARDS.
4.4. Carfilzomib
Carfilzomib is an approved antineoplastic drug for the
treatment of relapsed or refractory multiple myeloma
patients who have received 3 previous lines of thera-
pies [170,183,214]. It has been investigated in several
clinical trials for other malignancies such as Hodgkin
lymphoma (NCT02867618) and non-Hodgkin lym-
phoma like in diffuse large B-cell lymphoma
(NCT02073097) and mantle cell lymphoma
(NCT03891355). In detail, carfilzomib is a second-
generation antiproteasome with higher maximal per-
centage of proteasome inhibition at the maximum
tolerated dose than bortezomib [103]. This mechanism
leads to the irreversible inhibition of the 26S protea-
some, which plays a key role in the hallmarks of
myeloma, by binding to its chymotrypsin-like site of the
proteolytic core [62,227]. The multiple targets of pro-
teasome targeting encompass the NF-kB pathway, ER
stress, cell-cycle arrest, downregulation of growth factor
receptors and adhesion molecules expression, angio-
genesis inhibition as well as immunogenic cell death[103]. Carfilzomib was recently repurposed for COVID-
19 based on virtual docking screening, a structure-based
virtual screening method for molecules capable of
binding specific proteins in key binding sites or domains
[206]. Among several other promising drugs, including
eravacycline, elbasvir, lopinavir and valrubicin, carfil-
zomib was excellent in terms of binding free energy,
which is an important parameter for a rational drug
design targeting the SARS-CoV-2 main protease,
anticipating a potent antiviral activity in silico [206].
4.5. Toremifene
Toremifene is a selective modulator of oestrogen re-
ceptors used in the endocrine therapy of breast cancer
since 1997 [201]. Toremifene represents an alternative
drug to tamoxifen, showing a similar efficacy in patients
with advanced breast cancer [113]. Additionally, this
antioestrogen drug was shown to destabilise the envelope
glycoprotein of Ebola virus [222], leading to the inhibition
of the fusion between viral and endosome membranes
during intracellular trafficking [222]. The subsequent
in vivo studies confirmed the anti-Ebola activity of tor-
emifene regardless of its oestrogen-modulating activity,
by inhibiting virus entry and internalisation [97].
Finally, a recent in silico study identified toremifene
as a potential therapeutic approach against SARS-CoV-
2, particularly when combined to emodin [225]. Emodin
is a natural-derived compound with anticoronavirus
pharmacological properties, belonging to the traditional
Chinese medicine Lianhua Qingwen used for the pre-
vention and treatment of viral influenza [84,165]. The
authors suggested that toremifene interacts with several
key host coronavirus proteins including ribosomal pro-
teins like RPL19, HNRNPA1, NPM1, EIF3I,
EIF3F and EIF3E [225]. However, the exact mechanism
of its activity is still unclear. Based on the action on viral
entry, the use of this agent can be proposed for pro-
phylaxis of the infection and in patients with milder
disease, in the earlier stages of infection.
4.6. Zotatifin
Zotatifin is a potent and selective small molecule
inhibiting the eukaryotic initiation factor 4A (eIF4A)
[190]. eIF4A is an RNA helicase activated by the B-cell
receptor to stimulate several oncogenes linked to
tumour growth, cell survival and metastasis [82,190].
The inhibition of this target by zotatifin and other
synthetic molecules demonstrated promising antineo-
plastic preclinical efficacy [28,125,190]. For example,
zotatifin is being studied in a phase I/II dose-escalation
and cohort expansion clinical trial (n Z 45) as mono-
therapy for pancreatic cancer and other malignancies
(NCT04092673). Promisingly, a recent study published
in Nature suggests a potential of zotatifin repurposing
for COVID-19 [73]. Based on affinity-purification mass
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human proteineprotein interactions after cloning and
expressing the key SARS-CoV-2 proteins in human cells
[73]. Importantly, 66 targetable human proteins were
identified to be pharmacologically druggable by 69
compounds including 29 FDA-approved drugs [73].
Several of these compounds exhibited antiviral activities
against mRNA translation and Sigma1 and Sigma2
virus receptors expressed on host cells [73]. In this study,
zotatifin emerged as an effective drug in reducing viral
infectivity by inhibiting protein biogenesis through
eIF4A blockade along with other compounds such as
ternatin-4 [73,135]. The proposed disruption of the
translation of the Sigma proteins coupled to the direct
inhibitory activity against them seems a promising
strategy of drug targeting against SARS-CoV-2 infec-
tion and propagation, possibly indicated in the earlier
stages of the infection.4.7. Plitidepsin
Plitidepsin (also known as dehydrodidemnin B) is a
natural compound discovered in a Caribbean marine
organism (Aplidium albicans) [48]. Its antitumour effects
encompass several cancer targets such as angiogenesis
and cell survival [5,72]. Additionally, plitidepsin may
also enhance radiotherapy response by a bystander ef-
fect [155]. The activation of c-Jun N-terminal kinase is a
key mediator of plitidepsin sensitivity along with the
eukaryotic elongation factor 1 alpha 2 that were recently
suggested as potential predictive biomarkers of drug
response [50,126]. So far, the drug has been investigated
in several clinical trials for multiple myeloma, lym-
phoma, liposarcoma and prostate cancer [48]. Only one
phase III randomised and controlled trial has evaluated
the clinical activity of plitidepsin combined to dexa-
methasone in relapsed/refractory multiple myeloma
(NCT01102426/ADMYRE), showing mild improve-
ments in survival outcomes [180]. The development of
this drug has been halted or terminated because of the
arrival of competitive targeted agents as well as the poor
enrolment in clinical trials.
On the other hand, plitidepsin has also antiviral
properties, showing promising findings in the COVID-
19 treatment on in vitro models (Press release 1,
[136,137]). According to these models, plitidepsin blocks
the eEF1A protein in human cells that is required for
SARS-CoV-2 infection (Press release 2, [136,137]).
Therefore, the drug is being tested in a phase I Spanish
trial (NCT04382066/APLICOV) with the aim to assess
the safety and early efficacy of three doses of plitidepsin
(1.5, 2.0 and 2.5 mg/day) for three consecutive days in
patients requiring hospitalisation for COVID-19
(n Z 27). Based on the activity on a key mechanism
of the viral pathogenesis, the use of this drug can be
considered either in the earlier stages of infection, in amultidrug regimen and for patients with more advanced
disease, together with proper immunomodulators.
4.8. Dactinomycin
Historically, the anticancer drug dactinomycin was
discovered in Streptomyces parvulus bacterium by Sel-
man Waksman and colleagues in the 1940s [203] and
launched after its initial FDA-approval in 1964. This
intravenously administered cytotoxic antibiotic acts by
intercalation to DNA and interruption of RNA tran-
scription [38,87]. Recently, dactinomycin was shown to
induce immunogenic cell death, suggesting a direct
antineoplastic activity enhanced by immunomodulatory
properties [93]. In fact, this drug is used in combination
with other cytotoxic drugs in the management of a
broad array of solid malignancies, such as gestational
trophoblastic disease, Wilms’ tumour and Ewing sar-
coma [4,67,105,196].
The use of dactinomycin against coronaviruses was
firstly described in 1979 by Kennedy et al. in the context
of alpha-coronavirus 229E, involved in a spectrum of
respiratory diseases from upper to lower airways in-
fections [98]. Later on, Lewis et al. showed a potent
inhibition of the feline enteric coronavirus strain 79-
1683 in whole feline embryo cells [104]. Based on these
and subsequent evidence, dactinomycin was widely used
as an in vitro inhibitor of viral cellular transcription in
infected cells [197]. Recently, a combination of dacti-
nomycin and sirolimus showed a synergistic action
against SARS-CoV-2-host proteins [225]. In fact, the
association may inhibit DNA topoisomerase required
for RNA synthesis as well as mammalian target of
rapamycin (mTOR) signalling in human coronavirus
infected cells [225]. Notably, the mTOR pathway is a
target of sirolimus that has also shown a promising ac-
tivity against MERS-CoV in addition to its known
anticancer, immunosuppressive and antifungal proper-
ties [100]. However, these results for SARS-CoV-2 are
limited by their in silico nature and warrant more clinical
experiences beyond speculations. In addition, the use of
this antibiotic is associated with an adverse safety profile
when used at therapeutic doses as an antineoplastic
agent that may be less suitable for severely ill patients
with an acute infectious disease. In particular, the
emetogenesis and myelosuppression can deserve a spe-
cial consideration, and antiviral doses may be acceptable
only if lower, as expecting a better safety profile.
4.9. Valrubicin
Valrubicin is a semisynthetic derivative of the anthra-
cycline doxorubicin, used as intravesical topic treatment
for the management of refractory non-muscle invasive
bladder cancer [168]. The mechanism of action of val-
rubicin affects DNA synthesis and metabolism by
inhibiting the incorporation of nucleosides and
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erarchical virtual screening, recently Wang showed that
valrubicin alongside with other drugs, such as lopinavir
and carfilzomib inhibits the main protease of SARS-
CoV-2 [206]. Moreover, another report based on a ma-
chine-learning simulation has recently shown that val-
rubicin is a potential COVID-19 protease inhibitor [99].
However, no considerations on the effective doses have
been modelled: the clinical use as an agent for systemic
administration is not validated, being approved only as
a topic solution, and any speculation for the design of
clinical trials should account for the adverse safety
profile of this chemotherapeutic.
4.10. Leronlimab
Leronlimab (PRO 140) is a humanised monoclonal anti-
body targeting the CeC chemokine receptor type 5
(CCR5) on T lymphocytes [96]. The role of CCR5 in the
immunopathology of disease has been extensively studied
since its discovery as a co-receptor for human immuno-
deficiency virus entry in 1996 [21] (NCT03902522 and
NCT02859961). In addition, CCR5 is also expressed on a
broad array of cancers and it is linked to various cancer
hallmarks, particularly “avoiding immune destruction”
[96]. It is under investigation in trials for few cancers, such
as metastatic colon and breast cancers (NCT03838367),
for which several other inhibitors of CCR5 are being
developed (reviewed elsewhere: [96]. Previously, Chen
et al. demonstrated that mRNA transcripts of CCR5 and
other chemokine receptors were found upregulated in
animals infected by SARS-CoV [30]. Additionally,
enhanced production of these mediators was associated
with recruitment of inflammatory cells andT lymphocytes
influx into the lung parenchyma [30].
PRO 140 has shown a promising antiviral potency
with a high barrier to resistance and encouraging short-
term safety and tolerability [189]. A recently published
Preprint suggested that leronlimab disrupts the CCL5/
RANTES-CCR5 axis and restores immune homeosta-
sis in COVID-19 patients [133]. The authors observed a
marked CCR5 receptor occupancy on macrophages and
T lymphocytes, rapid drop of circulating IL-6, CD4/
CD8 ratio restoration and a significant decrease of pa-
tients’ viremia [133]. These encouraging findings boosted
the rapid entrance of leronlimab into two clinical trials
for mild to moderate and severe COVID-19 infection
(NCT04343651 and NCT04347239). The largest trial
using this drug is a randomised, double-blind and
placebo-controlled, two-arm phase IIb/III trial investi-
gating weekly leronlimab at a dose of 700 mg given
subcutaneously (NCT04347239). A multicentred enrol-
ment will include 390 patients with severe or critical
disease with a mortality rate after four weeks of treat-
ment as a primary end-point. Likewise, the other study
is a phase II (n Z 75) with a similar design that will
enrol patients with mild to moderate symptoms(NCT04343651). Patients will be randomised to receive
leronlimab (700 mg) or placebo weekly in a 2:1 ratio
with changes in total symptom score based on fever,
myalgia, dyspnea and cough at day 14 as a primary end-
point. Notably, the other outcome measures in this
clinical trial include serum changes of cytokines and
chemokines from baseline, CCR5 occupancy levels on
macrophages and Treg cells and CD3þ, CD4þ and
CD8þ T cell count from baseline. Based on the specific
action in-between the viral pathogenesis and the
immune-dysregulation, the use of this agent has been
proposed for patients with mild clinical COVID-19 to
prevent severe outcomes and reduce the related
mortality.4.11. Antineoplastic immune-checkpoint inhibitors
Based on the hypothesis suggesting the upregulation of
immune-checkpoints such as PD-1/PD-L1, cytotoxic T
lymphocyte antigen-4 (CTLA-4), lymphocyte
activation-gene-3 (LAG-3) and T cell membrane
protein-3 (TIM-3) pathways in excessive inflammatory
response during sepsis [132], these types of drugs were
repurposed beyond their use for the treatment of cancers
[132,147]. Importantly, a recent meta-analysis including
four studies showed PD-1 blockade improves patient
outcome in sepsis [219].
Camrelizumab is a humanised IgG4-kappa anti-
programmed cell death 1 (PD-1) monoclonal antibody
used in cancer immunotherapy [114]. The blockade of
PD-1 binding to its ligand PD-L1 enables reactivation of
cell-mediated immune response against cancer cells
[114]. Camrelizumab was tested in phases II/III clinical
trials for advanced or metastatic oesophageal squamous
cell carcinoma [91,92], osteosarcoma [212], relapsed or
refractory classical Hodgkin lymphoma [177,178] and
advanced hepatocellular carcinoma [145]. It received its
first approval in China for treating RRHCL patients
who received at least two lines of chemotherapy [114].
Additionally, it is currently being studied in two ongoing
phase III trials for local advanced nasopharyngeal car-
cinoma (NCT03427827) and gastric and gastroesopha-
geal junction adenocarcinoma (NCT04208347). The use
of anti-PD-1 inhibitor camrelizumab in COVID-19 pa-
tients with pneumonia is being evaluated in a Chinese
clinical trial (n Z 120; ChiCTR2000029806) in com-
parison with the standard supportive care and the
immunomodulatory agent thymosin.
Nivolumab and pembrolizumab are other immune-
checkpoint inhibitors (ICIs) that were successfully
introduced into the management of various solid can-
cers, particularly for melanoma [110,204]. These ICIs
are both humanised and fully human anti-PD-1 IgG4
monoclonal antibodies. Their marked clinical activity
depends on PD-L1 expression in some tumours, as well
as on emerging predictive biomarkers, such as tumour-
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drug response [51,81,158].
Nivolumab is currently used in a multicentred phase
II trial comparing its efficacy against tocilizumab,
GNS561 (a chloroquine analogue), and standard sup-
portive care in advanced or metastatic cancer patients
with COVID-19 (NCT04333914). A total of 273 par-
ticipants will be randomised to receive one of three
treatments based on two cohorts. Patients that are
asymptomatic or with mild disease will be prospectively
assigned to the group comparing nivolumab versus
GNS561 versus standard of care in a 1:1:1 ratio. Simi-
larly, in patients with moderate to severe symptoms,
nivolumab will be compared to GNS561 and tocilizu-
mab. Survival after four weeks of randomised treatment
is the primary end-point in this trial. Moreover, another
ongoing French phase II trial (n Z 92) is investigating
the safety and efficacy of nivolumab in COVID-19 pa-
tients requiring hospitalisation (NCT04343144). Pa-
tients will be randomly allocated to receive nivolumab
or standard of care (1:1 ratio). One pilot trial is also
testing nivolumab in the earlier setting of COVID-19, in
patients presenting with no or mild symptoms and not
hospitalised e to examine the role of this ICI as an
immune-enhancer, to accelerate the clearance of SARS-
CoV-2 (NCT04356508).
Pembrolizumab was also repurposed for COVID-19.
The COPERNICO is a multicentred two-arm phase II
trial (NCT04335305) that is currently enroling patients
with COVID-19 associated with pneumonia in Spain and
who are non-responsive to frontline therapy. Twenty-
four participants will be prospectively randomised to
receive intravenous tocilizumab plus pembrolizumab or
standard treatments (at physician’s choice). The use of
ICIs for COVID-19 is essentially intended as an immu-
nomodulator, based on the proposed role of PD-L1 axis
in the pathogenesis of ARDS and the expedited clearance
of SARS-CoV-2 with anti-PD-L1 therapies [163].
Accordingly, the studies ongoing are testing these ICIs
both for more severe cases, intending to attenuate the
exuberant cytokine production [166], and for mild pre-
sentations, to prevent the onset of the hyper-immune
pathological response and then dampen the viral repli-
cation [163]. Moreover, a recent report showed that PD-1
checkpoint inhibition in lung cancer patients who were
diagnosed with COVID-19 does not appear to affect the
prognostic outcomes [111]. Therefore, this provides a
promising rationale for immunotherapy, which seems to
have no unfavorable effects in this setting.
4.12. Kinase inhibitors
The blockade of kinase cascade is one of the successful
targeted strategies in treating cancer in the modern era
of oncology. Several kinase inhibitors including palbo-
ciclib, crizotinib, dabrafenib and imatinib, were intro-
duced in practice for various cancers [69]. The rationalefor using kinase inhibitors in COVID-19 is principally
based on their ability to inhibit host intracellular-viral
events particularly during trafficking induced during
the viral life cycle [140]. Viruses commonly use a number
of host kinases during their invasion and thus, they are
considered potential targets for kinase inhibitors
repurposing as broad-spectrum antivirals [66,164].
Several previous reports demonstrated potent antiviral
properties for kinase inhibitors in various virus-induced
diseases, including SARS-CoV infections
[8,17,35,46,100,128,129].
Imatinib is a marketed tyrosine kinase inhibitor for
chronic myeloid leukaemia and gastrointestinal stromal
tumours in the first-line setting [54,85]. The BCR-ABL1
oncoprotein with kinase activity was found to mediate
virus entry in several reports encompassing hepatitis C
and Ebola viruses [65,120]. In coronaviruses, recent
studies indicated that imatinib blocks cellecell and
cellevirus membrane fusions [36,175]. Additionally, in
in vivo and ex-vivo mouse models, the use of imatinib
protected the lungs from ischemia/reperfusion injury
[112,187], attenuated inflammation and vascular leak
[154] and prevented lung injury and death [182].
Clinically, the IMAGE-19 trial is a single-arm phase
II study in France that will enrol 90 elderly COVID-19
patients (NCT04357613). Early imatinib therapy at a
dose of 800 mg daily for two weeks will be evaluated to
prevent the progression to severe disease in patients >70
years with COVID-19. The efficacy of imatinib at a dose
of 100 mg is also being examined in combination with
hydroxychloroquine in the Spanish Covid-19HUF
phase II trial (n Z 165) (NCT04346147). Participants
will be randomised to receive either oral lopinavir/rito-
navir (protease inhibitors), imatinib or baricitinib (JAK
inhibitor), all combined to hydroxychloroquine. The
trial completion date is estimated in September 2020.
The COVERAGE study is a large French multiarm
phase III trial (NCT04356495) that will investigate the
efficacy of imatinib and several other experimental
treatments. A total of 1057 symptomatic COVID-19
patients will be randomly allocated to receive imatinib,
or telmisartan, or favipiravir, or hydroxychloroquine as
compared to a control group with the objective to
reduce the risk of hospitalisation or death in elderly
patients. Another phase III trial using imatinib versus
placebo for hospitalised COVID-19 patients is currently
recruiting in the United States (n Z 204,
NCT04394416). Given the acceptable safety profile of
imatinib and the several available generics, this seems to
be an effective strategy for clinical repurposing. The
drug repurposing of imatinib in COVID-19 has been
embedded for the early phases of the disease, commonly
referred to as the “viral response” phase [174]. Imatinib
seems to tackle the mechanisms of viral entry and
cellecell spread, functioning as an antiviral agent. In
this initial stage, the drug development is intended to
reduce the duration of the symptoms, minimise the
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sion to severe COVID-19.
Duvelisib is an orally bioavailable phosphatidylino-
sitol 3-kinase (PI3K) selective inhibitor that is being
studied for haematologic malignancies [94]. The
PI3KeAKTemTOR signalling is frequently dysregu-
lated in cancer as well as during hyperinflammation and
its therapeutic targeting is highly represented in ongoing
clinical trials. Duvelisib was investigated in the DUO
phase III trial and compared to ofatumumab for re-
fractory and relapsed chronic lymphocytic leukaemia
and small lymphocytic lymphoma [59]. It was approved
by the FDA in 2018 for treating adult patients with
relapsed or refractory chronic lymphocytic leukaemia or
small lymphocytic leukaemia after at least two prior
therapies [88]. There is currently one pilot phase II trial
examining the efficacy of duvelisib twice daily at a dose
of 25 mg for 10 d in COVID-19 patients as monotherapy
(NCT04372602). This single-arm study will test the hy-
pothesis that PI3K blockade could hamper the immune
system hyperactivation and therefore reduce lung
inflammation and interfere with the viral cycle. It is
estimated to enrol 25 participants, with overall survival
as a primary end-point. Notably, the PI3K inhibitors
including the drug duvelisib can cause lung inflamma-
tion and increase the risk for infections, as consistently
demonstrated for multiple compounds of this pharma-
cological class, and a special caution is warranted during
the clinical trials using this class of molecules.
The aberrant activation of the Bruton tyrosine kinase
has a key role in the tumourigenesis of B-cell lymphoma
[77]. Its abrogation seems to protect lungs from acute
immune-induced or lethal influenza-induced injuries
[60,102] as well as sepsis-induced injury [224]. Zanu-
brutinib is an orally administered irreversible inhibitor of
the Bruton tyrosine kinase [186,218,220]. This drug
showed a durable and high overall response rate in patients
with relapsed/refractory Mantle cell lymphoma [179].
Recently, zanubrutinib received accelerated FDA
approval for treating adult patients with this rare and
aggressive cancer who have received at least one line of
therapy [186]. For COVID-19, a phase II trial in the
United States is ongoing, aiming to dampen the disease-
related immune dysregulation and hyper-inflammation
(NCT04382586). This study is expected to randomise 52
participants to receive zanubrutinib combined to sup-
portive care versus placebo and to test the hypothesis of
increasing respiratory failure-free survival rates in patients
with pulmonary distress. Ibrutinib is another inhibitor of
Bruton kinase inhibitor, approved to treat indolent B-cell
malignancies and chronic graft-versus-host disease, now
being repurposed for COVID-19 [193]. An earlier experi-
ence with this drug in COVID-19 patients with cancer
showed marked improvements and resolution or near
resolution of COVID-19 symptoms during the follow-up[193]. In the same way, the iNSPIRE (NCT04375397) is
a phase II that will enrol 46 COVID-19 patients to
randomly receive ibrutinib versus placebo along with
standard supportive care. The trialists expect that ibrutinib
will reduce respiratory failure and their findings are ex-
pected to be released in September 2020.
Opaganib (ABC294640) is a first-in-class selective
inhibitor of sphingosine kinase-2 (sk2). This key enzyme
in lipid signalling promotes tumour growth, cell
proliferation and cytokine production during inflam-
mation [139,143,176e178]. It was previously noticed
that sk2 is the host factor that impacts the viral repli-
cation process of the chikungunya virus [149] and
maintains viral latency and survival in Kaposi’s
sarcoma-associated herpes virus [39]. This drug has an
orphan drug designation for cholangiocarcinoma [89]
and is being tested in clinical trials for patients with
metastatic castration-resistant prostate cancer
(NCT04207255) and advanced cholangiocarcinoma
(NCT03377179). It is also under development for
COVID-19-associated pneumonia in a phase II study
(NCT04414618). This is a randomised, double-blind,
placebo-controlled trial in 40 adult patients with posi-
tive pneumonia, using daily opaganib for two weeks.
Saracatinib (AZD0530) is a tyrosine kinase inhibitor
of the c-SRC family of proto-oncogenes. This pathway
mediates signal transduction for several cell functions
such as proliferation, cell-to-cell transmission, epithelial-
to-mesenchymal transition, vascular permeability, in-
vasion and metastasis [33,131]. Moreover, it interferes
with additional cell signalling such as PI3K/mTOR and
MAPK [151]. Saracatinib selectively abrogates this
enzyme and was investigated in several clinical trials for
recurrent osteosarcoma [11], platinum-resistant ovarian
cancer [116], unresectable thymic malignancy [76] and
cancer-induced bone pain [41]. SRC kinases have also a
role in endocytic trafficking [150] and there is a growing
body of evidence indicating the inhibitory properties of
viral replication of dengue viruses and MERS-CoV by
the anticancer agent saracatinib [42,171,228]. This
makes this drug a possible candidate for further in-
vestigations on other members of the Coronaviridae
family. In a recently published Preprint, molecular
modelling showed that saracatinib binds to the nucleo-
capsid protein sites of SARS-CoV-2 along with other
previously discussed drugs such as imatinib and camo-
stat [188]. To the best of our knowledge, saracatinib has
not entered into any COVID-19 clinical trial. The clin-
ical use of molecular blockers of PI3KeAKTemTOR,
Bruton tyrosine kinase, sk2 and c-SRC is anticipated to
exert immune-modulating rather than antiviral effect.
To date, the drug development of this group of tyrosine
kinase inhibitors is included in the protocols for hospi-
talised patients with severe COVID-19, to rescue the
immune-dysregulation and improve the outcome.
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Selinexor is a first-in-class orally bioavailable inhibitor
of Exportin-1 (XPO1) [185]. XPO1 is an export receptor
for various proteins and RNA molecules with oncogenic
properties and is frequently altered in cancer [7].
Moreover, it is implicated in several cancer pathways
including cell growth and survival, differentiation and
drug resistance [127]. XPO1 suppression by selinexor in
human clinical trials demonstrated promising results for
patients with heavily treated relapsed or refractory
multiple myeloma [29,152,202]. The drug received first
an accelerated approval by the FDA in the United
States of America (USA) in 2019 in combination with
dexamethasone [152]. The antiviral activity of selinexor
is based on its potential to interfere with host targets
including XPO1 that interacts with SARS-CoV-2 pro-
teins [73,194]. In fact, blockade of this nucleocytoplas-
mic transporter can sequester viral materials in the host
cell nucleus and therefore reduce its replication mecha-
nisms and viral load [194]. Moreover, selinexor has also
selective and potent anti-inflammatory effects on sepsis
pathophysiology [211]. Based on these concepts, two
phase II randomised and controlled trials of low dose
selinexor were initiated for COVID-19 patients with
moderate to severe disease (NCT04355676 and
NCT04349098). The largest trial that is currently
recruiting patients is single-blind and placebo-controlled
and is expected to enrol 230 hospitalised participants
with severe COVID-19 (NCT04349098).5. Perspectives
The COVID-19 pandemic continues to spread glob-
ally with 24,484,968 cases and 832,533 deaths registered
worldwide, including 6,016,069 cases only in the USA
(as of 27th August 2020). New effective therapeutics are
urgently needed, as the results from the first clinical
trials or experiences with drugs for COVID-19 are
mostly disappointing. There is a massive demand for
drug repurposing in this rapidly evolving setting, relying
on the benefit of a shorter drug development and the
capability to turn preclinical intuitions in clinical expe-
riences. In fact, it is a potential successful drug discovery
process, more efficient and resource sparing than the
classic drug development from early phases for new
molecules, taking generally a longer time (typically
10e15 years). While drug repurposing is not an excuse
to design low-quality clinical trials or emphasise biased
results from preliminary findings and non-controlled
cohorts, the possibility to use molecules with an estab-
lished safety profile certainly represents an advantage.
The US ClinicalTrials.gov database shows that 3100
clinical studies for COVID-19, including more than
1700 interventional trials (accessed as of 27-08-2020),
are ongoing, portraying the commitment of the globalmedical community to accelerate the COVID-19
research agenda e in a successful interplay between
laboratory researchers and clinical trialists, ultimately to
serve clinicians and improve patients’ care. However, in
the urgent need to provide a response to a burning
unmet need, many isolated smaller clinical trials or off-
label use of medicines outside the investigations have
been observed, perhaps fragmenting the research agenda
in uncoordinated silos e thus diluting the research effi-
ciency. The large proportions of ongoing clinical trials
are single-centred observational studies with high risk of
bias and therefore providing low level of evidence when
their findings are reported. The capacity to inform the
decision-makers is inevitably weak when the clinical
studies generate doubts over certainties. This was
recently outlined in a critical appraisal of registered
COVID-19 trials on ClinicalTrials.gov database [141].
In fact, only 13.6% of these clinical trials are prospective
cohorts that may provide level 2 evidence [141]. There-
fore, the lack of effective international cooperation is
suggested, along with the negligence of other key aspects
to tackle the pandemic, including the disease prevention
in high-risk populations. Another emerged critical issue
is the tremendous heterogeneity in the rates of COVID-
19 new cases across different geographic areas with a
significant decline in some countries that may halt and
decrease expected enrolment in ongoing clinical trials
[192]. The important number of launched monocentric
studies and the observed decline of incident COVID-19
cases in some countries should promote considering
adaptive study designs to fulfil enrolment [192]. For this
perspective, trialists are encouraged to follow master
protocols when testing their hypotheses, as suggested by
the World Health Organization, in the design of the
international adaptive trial SOLIDARITY (e.g.
NCT04330690). A significant experience with master
protocols in oncology and haematology was achieved,
which may accelerate drug development and reduce
ineffectiveness in urgent clinical trials [184].
Among the dozens of coronavirus drugs that are being
repurposed or in development, a number of anticancer
compounds are also being studied as potential future
drugs for COVID-19. At this time, the best option for
patients is the enrolment in clinical trials. In the current
scenario where no drug has provided a “parachute” effect
on the prognosis of patients with COVID-19, especially
with more severe disease, the use of off-label medicines
based on over-emphasised interpretations of the pre-
liminary data from small cohorts or anecdotes is strongly
discouraged. With nearly one thousand clinical trials
ongoing, there is virtually room to allocate much more
patients in truly promising clinical trials, tailoring specific
populations across the continuum of care e from the
prevention to the treatments and palliative care. The
notion is clear: treatment options in settings of high
medical unmet need can be improved only in controlled
clinical trials, both offering the most innovative
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engagement from established clinical interventions with
narrow added value, a common contingency observed
when no treatment is available for a particular disease.
Having an impact on health requires quality behind.
In response to the “high clinical unmet need” and to
support clinicians, who are facing the daily challenges
with the aim to manage severe health conditions asso-
ciated with dismal prognosis, the implementation of
clinical trials may serve to boost the access to treat-
ments, making treasure of such precious information. In
fact, the off-label use of some medicines, most strikingly
hydroxychloroquine almost everywhere, outside a clin-
ical trial or a registry-based accountability is the pri-
mordial error and the enhancer of confusions e
generated by the disconnect between the anecdotal
clinical perception of benefits and the objective data
collected. In this regard, the regulatory agencies for
medicines in many regions and countries have refor-
mulated simplified procedures and supported more
flexibility in the design, evaluation and adoption of
clinical trials, to meet the patients’ needs. For example,
the European Medicines Agency (EMA) has delineated
regulatory flexibilities to help pharmaceutical companies
cope with the consequences of the pandemic, empha-
sising the need to keep high-level of quality, safety and
efficacy for medicinal products developed for COVID-
19. The message is clear: patients’ safety and quality of
science in clinical trial conduction is non-negotiable
[52] (accessed 30-05-2020). EMA has established rapid
procedures through accelerated scientific advice, rolling
review and expedited treatment of the applications for
marketing authorisations [53] (accessed 30-05-2020).
The harmonisation of regulatory processes and
enhanced drug development must necessarily proceed in
parallel, committing to accelerate the drug repurposing,
ensuring safety thus prompting early interruptions of trials
when new safety signals emerge, or major results of activity
are collected. However, while endorsing the acceleration in
the revisions, decisions, approval and authorisation, the
regulators should commit to ensure the design of quality
clinical trials, pushing for the definition of the benefits
based on patients’ relevant end-points and dissecting the
reasonability and opportunity to favour surrogate end-
points in selected instances e when appropriate for the
setting and highly predictive or correlated with the mor-
tality outcomes e the truly important ones.
The high-throughput screening of approved mole-
cules capable to dock to the key protein domains of
SARS-CoV-2 pathogenesis or related to the immune-
dysregulation will identify thousands of possible com-
pounds, from in silico models. An important success for
this approach was recently achieved based on a library
profiling of approximately 12,000 clinical-stage or FDA-
approved compounds [153]. The authors of this paper
published in Nature identified various molecules such as
the kinase inhibitor apilimod that antagonise SARS-CoV-2 replication in vitro and in primary human lung
explant model [153]. While it is essential to boost the
drug-discovery based on approved medicines, to accel-
erate the drug development overall, the construct of
preclinical models should be in vitro and ex vivo strictly
Box 2. Useful resources and database
Website
The US Clinical Trials
Database
https://www.clinicaltrials.gov/
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committed for the research on COVID-19. This is an
effort of everyone. In the fight against COVID-19, the
entire chain of medical researches has rapidly become
multidisciplinary, truly intersected with specialists of
several branches, transversally positioned. Offering
technology and knowledge to develop the best science at
the service of a public health global emergency recalls
the humanitarian mandate of medical science e to
improve population health and wellbeing for all.
The hope is that drug repurposing to boost the dis-
covery of new treatments for human diseases will find the
right place and that this innovative and transversal
operational model of scientific research will get common,
to result in timely impact on populations at the most
effective and efficient utilisation of resources and knowl-
edge. Time forwasteful duplications based on competitive
conflicts should be over; the COVID-19 will enlighten the
solidarity in science, sublimating narcissism for the ulti-
mate goals of serving people, especially when facing the
hardest moments of their lives, for deadly diseases.
6. Conclusion
Controlling the SARS-CoV-2 pandemic warrants
multidisciplinary collaboration to find relevant treat-
ment options. From the evidence reviewed here, a
number of anticancer drugs seem to retain a promising
activity to treat patients with COVID-19. The high levelof evidence should still be the primary objective of the
clinical research, despite the critical circumstances dur-
ing a pandemic. Hence, testing a battery of known drugs
in clinical cohorts will certainly provide an additional
value to these molecules (for more information, see
Boxes 1 and 2). Although the ideas of using repurposed
anticancer drugs might be criticised because of the
toxicity profile of some of them, we believe that this
review article may provide inputs and guide the future
directions for clinical research e envisioning an
approach beyond the definition of separate medical
subjects by vaporising the common barriers between
medical disciplines. This might help address innovative
operational models and regulatory flexibilities in this
unique momentum of the international research, united
to control a global pandemic, committed to serve the
people in all over the world.
Funding
This research did not receive any specific grant from
funding agencies in the public, commercial or not-for-
profit sectors.
Conflicts of interest statement
Khalid El Bairi, Dario Trapani, Angelica Petrillo,
Cécile Le Page, Hanaa Zbakh, Bruno Daniele, Prof.
Rhizlane Belbaraka and Prof. Said Afqir have no COI
to declare. Prof. Giuseppe Curigliano has received
honoraria from Pfizer, Novartis, Lilly, Roche; fees for
expert testimony and medical education from Pfizer and
has participated in advisory boards for Pfizer, Roche,
Lilly, Novartis, Seattle Genetics, Celltrion.
Acknowledgements
For transparency and scientific publishing ethics, we
supported our manuscript by the Turnitin report of
plagiarism (Supplemental material 1). To encourage
international collaboration and continuous discussion
of this subject, we have created a project on Research-
Gate social network and we encourage the readers to
ask questions and comment on the topic following this
link: https://www.researchgate.net/project/COVID-19-
Cancer-and-Biomarkers.
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2020.09.014.
References
[1] Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK.
Prevention and treatment of cryptosporidiosis in
K. El Bairi et al. / European Journal of Cancer 141 (2020) 40e61 55immunocompromised patients. Cochrane Database Syst Rev
2007;1. https://doi.org/10.1002/14651858.CD004932.pub2.
CD004932. Published 2007 Jan 24.
[2] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary
vascular endothelialitis, thrombosis, and angiogenesis in covid-
19. N Engl J Med 2020. https://doi.org/10.1056/NEJ-
Moa2015432 [published online ahead of print, 2020 may 21].
[3] Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib. Recent Re-
sults. Canc Res 2018;212:119-132. https://doi.org/10.1007/978-3-
319-91439-8_6.
[4] Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW,
Lawrie TA. Chemotherapy for resistant or recurrent gestational
trophoblastic neoplasia. Cochrane Database Syst Rev 2016;
2016(1):CD008891. https:
//doi.org/10.1002/14651858.CD008891.pub3.
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Stahl M, et al. Inhibition of SARS-CoV-2 infections in engi-
neered human tissues using clinical-grade soluble human ACE2.
Cell 2020. https://doi.org/10.1016/j.cell.2020.04.004.
[122] Morimoto K, Koh M. Postoperative adjuvant use of carmofur
for early breast cancer. Osaka City Med J 2003;49(2):77-83.
[123] Motoo Y. Antiproteases in the treatment of chronic pancreatitis.
JOP 2007;8(4 suppl):533e7. 24.
[124] Mourad JJ, Azria P. Tocilizumab for severe COVID-19 pneu-
monia. Lancet Rheumatol 2020. https://doi.org/10.1016/S2665-
9913(20)30282-4.
[125] Müller D, Shin S, Goullet de Rugy T, et al. eIF4A inhibition
circumvents uncontrolled DNA replication mediated by 4E-BP1
loss in pancreatic cancer. JCI Insight 2019;4(21):e121951. https:
//doi.org/10.1172/jci.insight.121951.
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